• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

PRODUCT FILTERS

REGION

59
49
43
37
37

COUNTRY

37
13
12
12

CATEGORIES

  • 120
  • 68
  • 11
  • 9
  • 8
  • 5
  • 4
  • 3
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
SHOW ALL…

PRICE

169
204
208
224

PUBLISHED

7
13
23
224

PRODUCT TYPE

140
48
31
3
2

Search "Company Financials: Alkermes, Inc." returned 224 results.

Alkermes, Inc. Company Profile - Business Description, Strategies, SWOT and Financial Analysis

“Alkermes, Inc. Company Profile” is a comprehensive report on Alkermes, Inc.. The report provides complete information on the operations, organization structure and financial information details of...

October 2014
FROM

Alkermes, Inc. (ALKS) - Financial and Strategic Analysis Review

Alkermes, Inc., (Alkermes) is a biotechnology company that develops and manufactures extended-release injectable, pulmonary, and oral products for the treatment of prevalent, chronic diseases, such...

July 2010
FROM

Alkermes, Inc. - Product Pipeline Review - Q2 2011

Alkermes, Inc. – Product Pipeline Review – Q2 2011 Summary Global Market Direct’s pharmaceuticals report, “Alkermes, Inc. - Product Pipeline Review - Q2 2011” provides data on the Alkermes, Inc.’s...

July 2011
FROM

Alkermes, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

Project Synopsis: Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by...

June 2013
FROM

Alkermes Plc (ALKS) - Financial and Strategic SWOT Analysis Review

Alkermes Plc (ALKS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by The publisher...

July 2014
FROM

Alkermes, Inc. - Product Pipeline Review - H2 2011

Alkermes, Inc. – Product Pipeline Review – H2 2011 Summary Global Market Direct’s pharmaceuticals report, “Alkermes, Inc. - Product Pipeline Review - H2 2011” provides data on the Alkermes, Inc.’s...

November 2011
FROM

Alkermes, Inc. - Product Pipeline Review - Q4 2010

Alkermes, Inc. – Product Pipeline Review – Q4 2010 Summary Global Market Direct’s pharmaceuticals report, “Alkermes, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research...

November 2010
FROM

Alkermes, Inc. - Product Pipeline Review - Q4 2010

Alkermes, Inc. – Product Pipeline Review – Q4 2010 Summary Global Market Direct’s pharmaceuticals report, “Alkermes, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research...

November 2010
FROM

Research Update: Alkermes PLC Rating Raised To 'BB', Outlook Stable On Better-Than-Expected Performance; First-Lien Rating Also Raised Jul 13

Abstract Alkermes' performance for the fiscal year ended March 31, 2013, exceeded our expectations, with leverage declining to less than 2x, and we expect financial metrics to further improve over...

July 2013

Alkermes Inc. Nov 11

Abstract A track record of successful internal product development; The absence of near-term patent expirations; and Barriers to competitive entry for its injectable drug delivery technology and related...

November 2011

Recovery Report: Alkermes Inc.'s Recovery Rating Profile Jun 11

Abstract In conjunction with Waltham, Mass.-based Alkermes Inc.'s acquisition of Elan Drug Technologies, Standard & Poor's Ratings Services assigned preliminary recovery and preliminary issue-level...

June 2011

Biotech Funding Deals and Partnerships: Analysis of Recent Venture Capital and Corporate Capital Funding and Other Transactions

Recent Biotech Funding, Deals and Partnerships Nearly one out of every 8 dollars invested in companies are invested in biotech. Biotech investment has increased significantly in the past few years,...

May 2014
FROM

CreditStats: Biotechnology--U.S. Aug 12

Companies mentioned in this report are: - Amgen Inc. - Biogen Idec Inc. - Celgene Corp. - BioMarin Pharmaceutical Inc. (Unsolicited Ratings) - Gilead Sciences Inc. - Alkermes Inc. Standard...

August 2012

Rating and Forecast Report ALKERMES INC

Advanced academic research that brings you superior investment strategies in an actionable format. The most comprehensive and useful report available. The three models: Valuation Model, Forecast...

August 2015

Alkermes Inc. Assigned 'B+' Corporate Credit Rating; Outlook Is Stable Oct 11

Abstract Alkermes Inc., a Waltham, Mass.-based pharmaceutical technology company, acquired a similar operation from Elan Corp. plc for approximately $1 billion on Sept. 16, 2011, of which $450 million...

October 2011

Research Update: Alkermes Inc. Assigned 'B+' Corporate Credit Rating; Outlook Is Stable Oct 11

Abstract Alkermes Inc., a Waltham, Mass.-based pharmaceutical technology company, acquired a similar operation from Elan Corp. plc for approximately $1 billion on Sept. 16, 2011, of which $450 million...

October 2011

Alkermes Inc. Assigned Preliminary 'B+' Corporate Credit Rating; Stable Outlook Jun 11

Abstract Alkermes Inc., a Waltham, Mass.-based pharmaceutical technology company, is acquiring a similar operation from Elan Corp. plc for about $1.1 billion, of which $450 million will be funded from...

June 2011

Research Update: Alkermes Inc. Assigned Preliminary 'B+' Corporate Credit Rating; Stable Outlook Jun 11

Abstract Alkermes Inc., a Waltham, Mass.-based pharmaceutical technology company, is acquiring a similar operation from Elan Corp. plc for about $1.1 billion, of which $450 million will be funded from...

June 2011

Summary: Alkermes Inc. Nov 11

Abstract Our speculative-grade rating on Alkermes Inc. reflects a weak business risk profile exhibited by the uncertainty associated with a transformational acquisition, product concentration, dependence...

November 2011

Drug Delivery Series: The Market for Injectable and Implantable Drug Delivery Systems: Volume 2

Drug Delivery Series: The Market for Injectable and Implantable Drug Delivery Systems: Volume 2 The changing climate of injectable/implantable drug delivery system development has been fostered...

October 2001
Loading Indicator

Our Clients

Ikea Systems B.V. GlaxoSmithKline PLC BT Group PLC. Philips N.V. BSH Home Appliances Ltd Foreign & Commonwealth Office